A Phase I Study of YK012 in Primary Membranous Nephropathy

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).

Timeline

Start

2026-10

Primary completion

2027-11

Completion

2028-02

Drugs

Indications